171 related articles for article (PubMed ID: 37209594)
21. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
[TBL] [Abstract][Full Text] [Related]
22. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease.
Daull P; Amrane M; Ismail D; Georgiev G; Cwiklik L; Baudouin C; Leonardi A; Garhofer G; Garrigue JS
J Ocul Pharmacol Ther; 2020; 36(6):355-365. PubMed ID: 32493105
[TBL] [Abstract][Full Text] [Related]
23. Relevance of Lipid-Based Products in the Management of Dry Eye Disease.
Garrigue JS; Amrane M; Faure MO; Holopainen JM; Tong L
J Ocul Pharmacol Ther; 2017 Nov; 33(9):647-661. PubMed ID: 28956698
[TBL] [Abstract][Full Text] [Related]
24. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome.
Yang YJ; Lee WY; Kim YJ; Hong YP
Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33804439
[TBL] [Abstract][Full Text] [Related]
25. Reconsidering the central role of mucins in dry eye and ocular surface diseases.
Baudouin C; Rolando M; Benitez Del Castillo JM; Messmer EM; Figueiredo FC; Irkec M; Van Setten G; Labetoulle M
Prog Retin Eye Res; 2019 Jul; 71():68-87. PubMed ID: 30471351
[TBL] [Abstract][Full Text] [Related]
26. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial.
Craig JP; Muntz A; Wang MTM; Luensmann D; Tan J; Trave Huarte S; Xue AL; Jones L; Willcox MDP; Wolffsohn JS
Ocul Surf; 2021 Apr; 20():62-69. PubMed ID: 33401019
[TBL] [Abstract][Full Text] [Related]
27. Useful In Vitro Techniques to Evaluate the Mucoadhesive Properties of Hyaluronic Acid-Based Ocular Delivery Systems.
Graça A; Gonçalves LM; Raposo S; Ribeiro HM; Marto J
Pharmaceutics; 2018 Aug; 10(3):. PubMed ID: 30071584
[TBL] [Abstract][Full Text] [Related]
28. Human preocular mucins reflect changes in surface physiology.
Berry M; Ellingham RB; Corfield AP
Br J Ophthalmol; 2004 Mar; 88(3):377-83. PubMed ID: 14977773
[TBL] [Abstract][Full Text] [Related]
29. Effects of Menthol-Containing Artificial Tears on Tear Stimulation and Ocular Surface Integrity in Normal and Dry Eye Rat Models.
Ahn S; Eom Y; Kang B; Park J; Lee HK; Kim HM; Song JS
Curr Eye Res; 2018 May; 43(5):580-587. PubMed ID: 29419317
[TBL] [Abstract][Full Text] [Related]
30. Development of novel mucoadhesive hyaluronic acid derivate as lubricant for the treatment of dry eye syndrome.
Laffleur F; Dachs S
Ther Deliv; 2015; 6(10):1211-9. PubMed ID: 26606856
[TBL] [Abstract][Full Text] [Related]
31. A protocol for a single center, randomized, controlled trial comparing the clinical efficacy of 3% diquafosol and 0.1% hyaluronic acid in diabetic patients with dry eye disease.
Chen J; Chen Y; Qin G; Li L; Li M; Cheng Y; Zhuang S; Li Z; Zhang Q; Wu Y; Yang L; Moutari S; Moore JE; Xu L; He W; Yu S; Pazo EE; He X
Trials; 2023 Dec; 24(1):803. PubMed ID: 38087329
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Activity and Safety of a Low-Dose Hydrocortisone Tear Substitute in Patients with Dry Eye Disease.
Rolando M; Villella E; Loreggian L; Marini S; Loretelli C; Fiorina P; Barabino S
Curr Eye Res; 2023 Sep; 48(9):799-804. PubMed ID: 37334889
[TBL] [Abstract][Full Text] [Related]
33. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Shamloo K; Barbarino A; Alfuraih S; Sharma A
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
[TBL] [Abstract][Full Text] [Related]
34. Significance of mucin on the ocular surface.
Watanabe H
Cornea; 2002 Mar; 21(2 Suppl 1):S17-22. PubMed ID: 11995804
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model.
She Y; Li J; Xiao B; Lu H; Liu H; Simmons PA; Vehige JG; Chen W
J Ocul Pharmacol Ther; 2015 Nov; 31(9):525-30. PubMed ID: 26322539
[TBL] [Abstract][Full Text] [Related]
36. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease.
Schmidl D; Schmetterer L; Witkowska KJ; Unterhuber A; dos Santos VA; Kaya S; Nepp J; Baar C; Rosner P; Werkmeister RM; Garhofer G
Cornea; 2015 Apr; 34(4):421-6. PubMed ID: 25651494
[TBL] [Abstract][Full Text] [Related]
37. Development of a rabbit model of tear film instability and evaluation of viscosity of artificial tear preparations.
Nakamura S; Okada S; Umeda Y; Saito F
Cornea; 2004 May; 23(4):390-7. PubMed ID: 15097136
[TBL] [Abstract][Full Text] [Related]
38. Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease.
Calonge M; Sahyoun M; Baillif S; Gain P; Paw E; Mearza A; Cochener B
Eur J Ophthalmol; 2023 Jan; 33(1):188-195. PubMed ID: 35450456
[TBL] [Abstract][Full Text] [Related]
39. Hyaluronic acid in the treatment of dry eye disease.
Hynnekleiv L; Magno M; Vernhardsdottir RR; Moschowits E; Tønseth KA; Dartt DA; Vehof J; Utheim TP
Acta Ophthalmol; 2022 Dec; 100(8):844-860. PubMed ID: 35514082
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye.
You IC; Li Y; Jin R; Ahn M; Choi W; Yoon KC
J Ocul Pharmacol Ther; 2018 Oct; 34(8):557-564. PubMed ID: 30036099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
